This is what analysts have to say about Indivior PLC (LON:INDV) after last week.

October 13, 2017 - By Richard Conner

 This is what analysts have to say about Indivior PLC (LON:INDV) after last week.

Indivior PLC (LON:INDV) Ratings Coverage

Among 8 analysts covering Indivior Plc (LON:INDV), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Indivior Plc had 98 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Deutsche Bank on Monday, February 8. RBC Capital Markets maintained Indivior PLC (LON:INDV) rating on Wednesday, March 9. RBC Capital Markets has “Underperform” rating and GBX 140 target. Stifel Nicolaus maintained Indivior PLC (LON:INDV) rating on Thursday, December 10. Stifel Nicolaus has “Buy” rating and GBX 310 target. The rating was maintained by Deutsche Bank with “Buy” on Monday, June 6. RBC Capital Markets upgraded the stock to “Outperform” rating in Friday, July 28 report. The firm has “Buy” rating given on Friday, April 29 by Deutsche Bank. Citigroup maintained the shares of INDV in report on Wednesday, November 25 with “Buy” rating. The rating was maintained by Numis Securities on Thursday, May 4 with “Buy”. The stock has “Buy” rating by Deutsche Bank on Thursday, February 23. The stock of Indivior PLC (LON:INDV) earned “Buy” rating by Stifel Nicolaus on Friday, June 24. Below is a list of Indivior PLC (LON:INDV) latest ratings and price target changes.

08/09/2017 Broker: Jefferies Rating: Buy Old Target: GBX 540.00 New Target: GBX 358.00 Maintain
05/09/2017 Broker: Citigroup Rating: Neutral Old Target: GBX 280.00 New Target: GBX 280.00 Maintain
01/09/2017 Broker: Numis Securities Rating: Buy New Target: GBX 470.00 Maintain
11/08/2017 Broker: Jefferies Rating: Buy Old Target: GBX 490.00 New Target: GBX 540.00 Maintain
03/08/2017 Broker: RBC Capital Markets Rating: Outperform New Target: GBX 470.00 Maintain
28/07/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 390.00 New Target: GBX 470.00 Upgrade
27/07/2017 Broker: Numis Securities Rating: Buy New Target: GBX 490.00 Maintain
11/07/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
07/06/2017 Broker: Jefferies Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
31/05/2017 Broker: Numis Securities Rating: Buy New Target: GBX 490.00 Maintain

The stock decreased 1.00% or GBX 3.42 on October 13, reaching GBX 337.68. About 1.20 million shares traded. Indivior PLC (LON:INDV) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Indivior PLC is a specialty pharmaceutical company. The company has market cap of 2.43 billion GBP. The Firm is engaged in the development, manufacture and sale of buprenorphine prescription drugs for the treatment of opioid dependence (the Indivior Business). It has a 47.73 P/E ratio. The Company’s treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

More notable recent Indivior PLC (LON:INDV) news were published by: Prnewswire.com which released: “Indivior PLC Presents Results from the Phase 3 Pivotal Study of RBP-6000 …” on June 21, 2017, also Seekingalpha.com with their article: “Indivior Could Fall Further Once Generic Suboxone Arrives” published on September 12, 2017, Seekingalpha.com published: “Indivior Treads Forward In Opioid Addiction Market” on June 06, 2017. More interesting news about Indivior PLC (LON:INDV) were released by: Prnewswire.com and their article: “DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement” published on October 02, 2017 as well as Prnewswire.com‘s news article titled: “Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP …” with publication date: July 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.